Nicola Voyle

3.2k total citations
17 papers, 364 citations indexed

About

Nicola Voyle is a scholar working on Molecular Biology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Nicola Voyle has authored 17 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Physiology and 5 papers in Psychiatry and Mental health. Recurrent topics in Nicola Voyle's work include Alzheimer's disease research and treatments (13 papers), Dementia and Cognitive Impairment Research (5 papers) and S100 Proteins and Annexins (5 papers). Nicola Voyle is often cited by papers focused on Alzheimer's disease research and treatments (13 papers), Dementia and Cognitive Impairment Research (5 papers) and S100 Proteins and Annexins (5 papers). Nicola Voyle collaborates with scholars based in United Kingdom, Switzerland and United States. Nicola Voyle's co-authors include Paul Delmar, Rachelle S. Doody, Gregory Klein, Danielle Abi‐Saab, Paulo Fontoura, Carsten Hofmann, Monika Baudler, Geoffrey A. Kerchner, Mirjana Andjelković and Smiljana Ristič and has published in prestigious journals such as Neurology, Journal of Alzheimer s Disease and JAMA Neurology.

In The Last Decade

Nicola Voyle

16 papers receiving 353 citations

Peers

Countries citing papers authored by Nicola Voyle

Since Specialization

Citations

This map shows the geographic impact of Nicola Voyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Voyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Voyle more than expected).

Fields of papers citing papers by Nicola Voyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Voyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Voyle. The network helps show where Nicola Voyle may publish in the future.

Co-authorship network of co-authors of Nicola Voyle

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Voyle. A scholar is included among the top collaborators of Nicola Voyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Voyle. Nicola Voyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Biomarker treatment effects in two phase 3 trials of gantenerumab 2025 ·Alzheimer s & Dementia ·Tobias Bittner, Mattéo Tonietto, Gregory Klein, (unknown), (unknown), Nicola Voyle, Paul Delmar, Marzia A. Scelsi, (unknown), (unknown), Muhamed Baraković, Antonio Napolitano, (unknown), (unknown), Kaj Blennow, Frederik Barkhof	2
2	Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease 2024 ·JAMA Neurology ·Stephen Salloway, (unknown), Nicola Voyle, Christopher Lane, Gregory Klein, (unknown), Simona Rossomanno, (unknown), Szofia Bullain, Frederik Barkhof, Tobias Bittner, (unknown), (unknown), Roxana Aldea, Merçé Boada, Janice Smith, Rachelle S. Doody	15
3	GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD) 2023 ·Alzheimer s & Dementia ·Christopher Lane, Janice Smith, Richard Perry, Timo Grimmer, Claire J. Lansdall, Nicola Voyle, Paul Delmar, Tobias Bittner, Gregory Klein, Dietmar Schwab, (unknown), Stephen Salloway, Jeffrey L. Cummings, Monika Baudler, Paulo Fontoura, Rachelle S. Doody, (unknown)	0
4	Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab 2021 ·The Journal of Prevention of Alzheimer s Disease ·Gregory Klein, Paul Delmar, Geoffrey A. Kerchner, Carsten Hofmann, Danielle Abi‐Saab, Albert A. Davis, Nicola Voyle, Monika Baudler, Paulo Fontoura, Rachelle S. Doody	44
5	Evaluation of the Elecsys NeuroToolKit panel in early Alzheimer's disease populations across six clinical trials 2021 ·Alzheimer s & Dementia ·Christina Rabe, (unknown), Nicola Voyle, (unknown), (unknown), Marian Quan, Tobias Bittner	1
6	Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis 2019 ·Alzheimer s Research & Therapy ·Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi‐Saab, Mirjana Andjelković, Smiljana Ristič, Guoqiao Wang, Randall J. Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura, Rachelle S. Doody	158
7	O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION 2018 ·Alzheimer s & Dementia ·Mirjana Andjelković, Danielle Abi‐Saab, Paul Delmar, Nathalie Pross, Nicola Voyle, Gregory Klein, (unknown), Smiljana Ristič, Ferenc Martényi, Paulo Fontoura, Rachelle S. Doody	5
8	O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION 2018 ·Alzheimer s & Dementia ·Danielle Abi‐Saab, Mirjana Andjelković, Nathalie Pross, Paul Delmar, Nicola Voyle, Gregory Klein, (unknown), Smiljana Ristič, Ferenc Martényi, Paulo Fontoura, Rachelle S. Doody	6
9	O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES 2018 ·Alzheimer s & Dementia ·Gregory Klein, Paul Delmar, Carsten Hofmann, Danielle Abi‐Saab, Mirjana Andjelković, Smiljana Ristič, Nicola Voyle, John Seibyl, Kenneth Marek, Ferenc Martényi, Monika Baudler, Paulo Fontoura, Rachelle S. Doody	3
10	Optimizing the Gantenerumab Phase 3 Dosing Regimen Through PK/PD Modeling and Clinical Trial Simulations (P6.179) 2018 ·Neurology ·Carsten Hofmann, Ronald Gieschke, Sylvie Retout, (unknown), Nicola Voyle, Paul Delmar, (unknown)	1
11	O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY 2018 ·Alzheimer s & Dementia ·Nicola Voyle, Danielle Abi‐Saab, Gregory Klein, Carsten Hofmann, Paul Delmar, Nathalie Pross, Mirjana Andjelković, (unknown), Ferenc Martényi, Paulo Fontoura, Rachelle S. Doody	9
12	[P1–048]: RELATIONSHIP BETWEEN VASCULAR PATHOLOGY AT BASELINE AND AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN PRODROMAL AD PATIENT POPULATION IN SCARLET ROAD STUDY 2017 ·Alzheimer s & Dementia ·Mirjana Andjelković, Danielle Abi‐Saab, Paul Delmar, Nathalie Pross, Nicola Voyle, (unknown), Robert Lasser, (unknown)	1
13	[P1–045]: THE EFFECT OF 6 MONTHS’ DOSING ON THE RATE OF AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN THE MARGUERITE ROAD STUDY 2017 ·Alzheimer s & Dementia ·Danielle Abi‐Saab, Mirjana Andjelković, Paul Delmar, Nicola Voyle, (unknown), Robert Lasser	9
14	Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins 2016 ·Translational Psychiatry ·Nicola Voyle, (unknown), Petroula Proitsi, Nicholas J. Ashton, Alison L. Baird, Chantal Bazenet, Abdul Hye, Sarah Westwood, Raymond T. Chung, Malcolm Ward, Gil D. Rabinovici, Simon Lovestone, Gerome Breen, Cristina Legido‐Quigley, Richard Dobson, Steven J. Kiddle, (unknown)	19
15	Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid 2016 ·Journal of Alzheimer s Disease ·Nicola Voyle, (unknown), Hamel Patel, Amos Folarin, Stephen Newhouse, Caroline Johnston, Pieter Jelle Visser, Richard Dobson, Steven J. Kiddle	11
16	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer’s Disease Diagnosis 2015 ·Journal of Alzheimer s Disease ·Nicola Voyle, Aoife Keohane, Stephen Newhouse, Katie Lunnon, Caroline Johnston, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Simon Lovestone, Angela Hodges, Steven J. Kiddle, Richard Dobson	45
17	Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology 2015 ·Journal of Alzheimer s Disease ·Nicola Voyle, David Baker, Samantha C. Burnham, (unknown), (unknown), (unknown), Cristina A. Tan Hehir, Chantal Bazenet, Simon Lovestone, Steven J. Kiddle, Richard Dobson	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact